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I . INTRODUCTION 
A. ASPECTS O F P R O T E O L Y T I C PATHOMECHANISMS IN INFLAMMATION 
There are a multitude of inflammatory mediators and reactions investigated hitherto and 
claimed as being at least contributory to the development of an inflammatory process. 
Proteolysis-induced pathomechanisms seem to play a major role in the primary response to 
and the ultimate outcome of the organism to inflammatory stimuli such as tissue destruction 
due to multiple trauma and major surgery or invasive microbes and endotoxins in sepsis. 
Independent of the etiology of the insult, the inflammation response is primarily directed 
towards inactivating and eliminating the deleterious agents and to initiate the process of 
repair and healing. Yet, the activation of the complex interacting cellular and humoral defense 
mechanisms necessary for this purpose also carries with it the risk of damaging healthy 
tissue, thus perpetuating the inflammatory process. In this respect, the lysosomal serine 
proteinase elastase and the cysteine proteinase cathepsin Β of the primary inflammatory 
cells, polymorphonuclear (PMN) granulocytes and monocytes/macrophages, respectively, 
are supposed to be potent effectors of proteolytic tissue damage i f they are discharged 
extracellularly in high amounts during activation and disintegration of the phagocytes. More­
over, proteinases of humoral origin (plasma kallikrein, thrombin, plasmin, complement 
esterases) and protein split products (permeability increasing fibrinopeptides and fibrin mono­
mers, fibronectin peptides, complement-derived anaphylactic factors, such as C3a, C4a, and 
C5a, vasoactive kinins, arachidonic acid metabolites, etc.) generated by their proteolytic 
action have been proven to be of major importance as strong stimulators of the primary 
defense cells. 
In addition to lysosomal proteinases, highly reactive oxygen species produced by the 
respiratory burst are also extracellularly liberated during phagocytosis. This means that vital 
structural elements (basal membranes, cell receptors, fibronectin, elastin, collagens, pro­
teoglycans, etc.) as well as humoral factors including a wide variety of plasma proteins 
(review of literature in Jochum1 and Machovich and Owen2) in close vicinity to the phag-
ocytizing cells may be impaired unless the lysosomal proteolytic enzymes and oxidants are 
inactivated by their physiological regulators, the proteinase inhibitors (a,-proteinase inhib­
itor, a2-macroglobulin, cysteine proteinase inhibitors) and antioxidants (superoxide dis-
mutase, catalase, glutathione redox system, ceruloplasmin). 
Yet, due to an overstressed phagocytic activity of PMN granulocytes and monocytes/ 
macrophages during severe inflammation, the main antagonist of PMN elastase, the a,-
proteinase inhibitor (a,PI), is highly susceptible not only to proteolytic cleavage by cysteine 
and metallo proteinases released from the mononuclear cells, but also to oxidative denatur-
ation of the reactive inhibitory site in the molecule.3 This enables an unrestricted local 
digestive activity by PMN elastase combined with fatal consequences for the hemostasis 
system. As shown by several authors (reviewed in References 1 and 2), PMN elastase can 
easily degrade and inactivate the principal inhibitors (antithrombin I I I , a2-plasmin inhibitor, 
plasminogen activator inhibitor 1, Cl-inactivator) of proteinases of the blood cascade systems 
(clotting, fibrinolysis, complement), thus allowing the maintenance of life-threatening con­
sumption of hemostasis factors and the additional production of potent stimulators of the 
phagocytes as mentioned above. Moreover, the proteolytic inactivation of the blood cascade 
inhibitors may be greatly enhanced by their oxidative denaturation in the surroundings of 
phagocytizing cells.4 
Just recently the proteolytic degradation of the main human cysteine proteinase antag­
onists, cystatin C and kininogen, by PMN elastase has also been demonstrated,5-6 which 
may further aggravate the destructive potency of monocyte/macrophage-derived cysteine 
proteinases which are extracellularly discharged due to serious incidents such as multiple 
trauma and sepsis. 
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FIGURE 1. Schematic depiction of humoral and cellular proteolytic pathomechanisms involved in the devel­
opment of multiple organ failure (MOF). Destructive proteases (elastase, cathepsin B) and other cell constituents 
are released after activation of the phagocytes by blood cascade proteinases (plasma kallikrein, factor Xlla , thrombin, 
etc.) and polypeptides (fibrinogen and fibronectin split products, complement factors C3a and C5a, etc.). For 
detailed explanations see text. 
The tremendously complex interrelationship of cellular and humoral proteolytic patho­
mechanisms eventually contributing to the development of multiple organ failure (MOF) in 
the course of severe acute inflammation is depicted in a very simplified version in Figure 
1. A comprehensive review of literature on this topic is given by Jochum,1 Jochum and 
Fritz, 7 8 and Assfalg-Machleidt et al . 9 
B. R A T I O N A L E FOR T H E R A P E U T I C USE O F PROTEINASE INHIBITORS 
To obtain fundamental information about the extent to which proteinases may participate 
in the initiation and perpetuation of inflammatory processes, the following indications — 
as a modification of the Koch-Dale criteria — have to be proven in clinical and/or exper­
imental studies: 
1. The release of the lysosomal proteinases (e.g., PMN elastase, cathepsin B) and the 
activation of proteolytic blood cascade enzymes has to be verified in correlation to 
the severity of the inflammation. 
2. The consumption of proteinase inhibitors and other plasma factors susceptible to pro­
teolytic degradation should coincide with the occurrence of proteolytic activity. 
3. Specific split products of functional proteins generated by the proteolytic action of 
lysosomal proteinases have to be shown in correlation with the extracellular release 
of these enzymes. 
4. Administration of exogenous phagocyte proteinases in animals should elicit reactions 
similar to those observed during acute inflammation. 
5. The use of specific exogenous proteinase inhibitors as therapeutic tools should prevent 
or at least reduce to some extent severe signs of inflammation. 
In the following part of this chapter, characteristic results on these demands primarily 
obtained from our own clinical and experimental studies dealing with multiple trauma and/ 
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or septicemia are given in more detail. Using the same specific test systems, these findings 
and those of other authors, which will be also briefly mentioned, demonstrate clearly the 
involvement of proteolysis-induced pathomechanisms in acute inflammation regardless of 
the inciting cause. Therefore, proteinase inhibition may be an indispensable and therapeutic 
approach to reduce the incident of organ failure and lethality in such disease states in the 
future. 
I I . M E T H O D O L O G Y 
Serially drawn citrated plasma, bronchoalveolar lavage fluid (BALF), and peritonitis 
exudate samples were used to quantify proteinases, inhibitors, and plasma proteins as well 
as their split products. 
Measurements of the lysosomal serine proteinase PMN elastase were carried out with 
a commercially available, highly specific two-site sandwich enzyme immunoassay kit (E. 
Merck, Darmstadt, Germany), which detects elastase only as an inactive complex with ctjPI 
(detailed description in Neumann and Jochum10). The normal range of circulating complexed 
elastase in healthy people due to the physiological turnover of PMN cells is between 60 and 
120 ng/ml without the proteolytically active enzyme being detectable. Since, in contrast to 
plasma, BALF and peritonitis exudate samples may contain active elastase in addition to 
the complex, parts of these specimens were also incubated with a surplus of o^PI in vitro 
and reassayed for an increase in elastase — c^PI complex as a measure of enzymatic elastase 
activity in vivo. 
The cysteine proteinase cathepsin Β activity (upper normal plasma level: 50 mU/1) was 
quantified using a specific fluorometric peptide substrate as described by Assfalg-Machleidt 
et al . 9 Caseinolytic activity of local body fluids due to active elastase and/or cathepsin Β 
was detected using resorufin-labeled casein (Boehringer, Mannheim, Germany) as a sub­
strate. The method is outlined in detail by the manufacturer (Boehringer). 
The coagulation proteinases plasma kallikrein and thrombin were estimated by their 
cleavage activity on the chromogenic peptide substrates S-2302 (Kabi, Stockholm, Sweden) 
and Chromozym TH (Boehringer, Mannheim, Germany), respectively, after the turnover of 
the proenzymes to the active proteinases. 
The inhibitory activities of antithrombin I I I (AT III) and o^PI were measured with 
commercially available test systems (Coatest Antithrombin, Kabi, Stockholm, Sweden; 
aj-Antitrypsin Farbtest, Boehringer, Mannheim, Germany) applying chromogenic peptide 
substrates for thrombin (S-2238) and trypsin (ΒΑΡΑ), respectively. The antigen levels of 
the inhibitors were quantified with commercial radial immunodiffusion plates (NOR-Partigen 
plates, Behringwerke, Marburg, Germany). 
Opsonic activity, antigen levels and split products of the opsonins IgG and complement 
factor C3 were determined as outlined in Billing et a l . 1 1 1 3 and Machleidt et a l . 1 4 
An elastase-specific split product of the Αα-chain of fibrinogen, called fibrino-elastase-
peptide (FEP; equivalent to the Act 1-21 peptide described by Weitz et al . 1 5 ) , was quantified 
with a two-step competitive immunoassay just recently developed in our laboratory by 
Gippner-Steppert.16 
Clinical methods, criteria for grading the severity of the diseases, treatment of patients, 
and experimental therapeutic studies are extensively described in the original publications 
cited in the following sections. 
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I I I . RESULTS AND DISCUSSION 
A. PROTEOLYSIS-INDUCED PATHOMECHANISMS IN HUMANS 
1. Multiple Trauma and Infection 
In an early preliminary clinical attempt including 27 polytraumatized patients, we were 
able to show that severe injuries of at least two body regions (thorax, abdomen, skeletal 
system) induced a prompt and, more or less, long-lasting release of PMN elastase into the 
circulation of the patients (Dittmer et al . 1 7 ) . Measurements were carried out every 4 h up 
to the 28th h and thereafter every 6 h up to the 52nd posttraumatic hour. The maximum 
increase between five- and 30-fold of normal PMN elastase plasma levels correlated well 
with the clinical injury severity score within 8 to 12 h after the traumatic event. Yet, due 
to logistic limitations of the study, it was not possible to evaluate a predictive value of the 
extracellularly discharged PMN elastase for the development and outcome of trauma-induced 
(multiple) organ failure. 
In a second approach concerning 24 multiply injured patients, we could demonstrate 
that the primary activation of PMN granulocytes, immediately after the polytraumatic event, 
is followed by repetitive increases of complexed elastase in plasma in those patients who 
developed ARDS (adult respiratory distress syndrome) and additional organ failure (Jochum 
et al . 1 8 ) . This multiple organ insufficiency in our patients was mainly due to septic com­
plications. In agreement with findings of Nuytinck et a l . 1 9 and Redl et a l . 2 0 elevated plasma 
levels of elastase correlated well with the severity of injuries and the occurrence of MOF. 
Moreover, they discriminated to a reasonable degree at an early stage in the clinical course 
between later survival or mortality. 
To clarify further the potential role elastase — and additionally cathepsin Β — may 
play in progressive posttraumatic complications, we recently accomplished a more extended 
exploration. One hundred severely injured patients, fulfilling previously defined entry cri­
teria, have been enrolled in a prospective study (directed by Drs. Nast-Kolb and Waydhas, 
Surgical Clinic City, University of Munich) on inflammatory mediators and MOF associated 
with polytraumatic events (Nast-Kolb et a l . , 2 1 Waydhas et al . 2 2 ) . The collection of blood 
samples and recording of clinical data were started within 30 min after arrival of the patients 
in the emergency room (about 1 h after the accident) and continued on a 6-h basis up to 48 
h. Subsequently, the monitoring interval was extended to 24 h for a period of 14 d. Thereafter, 
the clinical course was recorded until either transfer to a general ward or death of the patient. 
Retrospectively, the patients could be assigned to three different groups: 16 out of them 
died due to MOF between 3 and 28 d (mean survival time: 16 d) after the traumatic incident 
(group I ) , 47 patients survived the development of organ failure (group II ) , and 37 patients 
overcame the accident without evident signs of organ dysfunctions (group II I ) . 
The extracellular release of PMN elastase and monocyte/macrophage-derived cathepsin 
Β into plasma of the patients within the three outcome groups is depicted in Figure 2. PMN 
elastase was elevated in all groups significantly above normal (upper range 120 ng/ml) within 
1 to 2 h after trauma and showed an additional increase up to the 12th posttraumatic hour. 
The differences between mean plasma levels in patients with and without organ failure 
(groups 1 and 2, and group 3, respectively) were highly significant (p <0.01) throughout 
the entire observation period. Moreover, patients dying due to organ failure (group I) and 
those who survived organ dysfunctions (group II) could be significantly (p <0.05) differ­
entiated according to their mean PMN elastase plasma concentrations from the third post-
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FIGURE 2. Mean values ( ± SEM) of polymorphonuclear elastase (in complex with a,-proteinase inhibitor) and 
cathepsin Β in plasma of multiply injured patients assigned to three outcome groups: Group I (n = 16), nonsurvivors 
with multiple organ failure ( * — * ) ; group I I (n = 47), survivors with reversible organ failure ( o — o ) ; group I I I 
(n = 37), survivors without organ failure ( + — + ). (*) ρ <0.05, (**) ρ <0.01 for group I vs. group I I ; ( · ) ρ 
<0.05, ( · · ) ρ <0.01 for group I vs. group I I I ; (Α) Ρ <0.05, (AA) Ρ <0.01 for group I I vs. group I I I . 
traumatic day onward. Cathepsin Β plasma levels reached their maxima at least 6 h before 
complexed PMN elastase (Figure 2). This early cathepsin Β activity in circulating blood 
proved to be a sensitive and specific predictor of subsequent developing organ failure. Yet, 
it did not discriminate between lethal (group I) and reversible (group II) dysfunctions at that 
time. In contrast to PMN elastase, cathepsin Β activity returned to only slightly elevated 
levels within 3 d in all patients (Figure 2), thus, not allowing a further differentiation of the 
three outcome groups. From these data, the conclusion can be drawn that the early release 
of lysosomal phagocyte proteinases, after a severe traumatic event, contributes to the oc­
currence of forthcoming organ failure, and that at least the ongoing discharge of PMN 
elastase may be involved in the exacerbation of the clinical situation. The latter seems to 
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FIGURE 3. Plasma levels of polymorphonuclear elastase (in complex with α,-proteinase inhibitor) and fibrino-
elastase-peptide (FEP) in a polytraumatized patient with lethal multiple organ failure. (Resp.F.) respiratory failure; 
(DIC) disseminated intravascular coagulation; (Ren. F.) renal failure; (ARDS) acute respiratory distress syndrome; 
(Hep.F.) hepatic failure. 
be confirmed by the appearance of the elastase-induced split product FEP of fibrinogen in 
correlation to the continuous release of elastase and the development of lethal MOF as 
outlined in Figure 3 for the first time for a severely injured patient. 
Since blunt trauma as well as bacterial complications and sepsis initiate the release of 
phagocyte proteinases. 7· 1 9· 2 0· 2 3 we compared the plasma level patterns of PMN elastase and 
cathepsin Β in subgroups of trauma patients suffering from infection/sepsis and those who 
did not develop these complications.22 In about 70% of patients with organ failure, early 
dysfunctions (usually respiratory insufficiency) became obvious during the first two post­
traumatic days. Late organ failure, predominantly due to liver failure, emerged after the 
third day posttrauma, whereas MOF was diagnosed in 32% of all group I and I I patients 
between day six and eight. Infections appeared around the third day post trauma and remained 
fairly constant for about 1 week. Bacterial sepsis occurred slightly delayed. According to 
the three outcome groups infection/sepsis was verified for 81%/50% of the patients in group 
I , for 74%/36% in group I I , and for 24%/5% in group I I I , respectively. Summarizing the 
clinical data, it turned out that in 97% of the patients with an early onset of organ failure, 
infection started at least 2 d later than the organ insufficiencies. In only half of those patients, 
infection or sepsis led to a consecutive deterioration of the clinical situation. In contrast, in 
50% of the 18 patients with a late onset of organ failure, infection and sepsis preceded the 
disturbance of organ functions and seemed to have pathogenic significance. Interestingly, 
only PMN elastase showed an obvious correlation with infection or sepsis. Since significantly 
higher plasma levels were measurable even before onset of these entities compared to a 
similar posttraumatic course without such complications (shown in Figure 4 for group I I 
patients), the conclusion can be drawn that the granulocytic proteinase may facilitate and 
maintain the occurrence of posttraumatic infections and sepsis. This assumption is also 
confirmed by recently published data on progressive organ failure in a prospectively studied 
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FIGURE 4. Mean values ( ± S E M ) of PMN elastase (in complex with α,-proteinase inhibitor) in plasma of 
trauma patients with reversible organ failure (group I I ) . (a) Patients with infection ( * — * ; η = 35) and without 
infection (ο—Ο; n = 12) — (*) ρ <0.05 infection vs. no infection, (b) Patients with sepsis ( * — * , η = 17) and 
without sepsis ( o — o ; n = 30) — (*) ρ <0.05, (**) ρ <0.01 sepsis vs. no sepsis. 
group of well-defined, multiply injured patients.24 Although no information is given about 
the time of onset of the septic state, significantly higher PMN elastase plasma levels were 
presented for 18 septic, in comparison to 17 nonseptic patients from the 24th h up to the 
8th d posttrauma. 
Interestingly, the main clotting inhibitor, AT I I I , showed a significantly lower inhibitory 
activity (p <0.01) in plasma of group I and I I patients vs. those of group I I I during the 
whole observation period and between nonsurvivors (group I) vs. survivors with organ failure 
Jochum, Machleidt, and Fritz 343 
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FIGURE 5. Mean values ( ± S E M ) of antithrombin I I I inhibitory activity in plasma of multiply injured patients 
assigned to three outcome groups. For legend see Figure 2. 
(group II) beginning with the first posttraumatic week onwards (Figure 5). Similar results 
were obtained concerning the rapid turnover of the coagulation proenzymes prekallikrein 
and prothrombin to kallikrein and thrombin, the latter being the essential target proteinase 
of AT I I I . Thus, plasma levels of AT I I I , prekallikrein, and prothrombin, which were 60% 
below normal in the early posttraumatic phase, were highly associated with the later ap-
pearance of severe organ dysfunctions, indicating that in addition to the release of lysosomal 
proteinases, an overwhelming activtion of the humoral proteolytic cascade systems is also 
conducive to the perpetuation of the posttraumatic inflammatory process. Yet, neither levels 
of AT I I I nor those of the clotting proenzymes differentiated between septic and nonseptic 
patients in any of the three outcome groups.22 The highly predictive value of early, low AT 
I I I inhibitory activities for a forthcoming exacerbation of posttraumatic organ dysfunctions 
eventually leading to ARDS and MOF was also emphasized by Schramm and Spannagl25 
reporting on 57 prospectively studied trauma patients. 
In this clinical study on multiply injured patients (a detailed study protocol is given by 
Sturm 2 6), we have been especially interested in local proteolysis-induced mechanisms, which 
might be involved in the pathogenesis of the most severe lung dysfunction, ARDS. Daily 
drawn BALF samples (method described by Obertacke et al. 2 7) allowed us to confirm a 
significantly increased local discharge of the phagocyte proteinases, elastase, and cathepsin 
B, in subjects at high risk to develop ARDS (Jochum28). Although the ctjPI antigen levels 
in all BALF specimens of the traumatized patients were far above the normal values of 
healthy volunteers, these amounts were apparently not sufficient in most cases to completely 
inhibit the PMN elastase released in the local epithelial milieu of the alveoli despite an up-
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FIGURE 6. Proteolytic activity (degradation of resorufin-casein with and without addition of α,-proteinase 
inhibitor) and free PMN elastase in serial bronchoalveolar lavage fluids of a severely traumatized patient. Acute 
respiratory distress syndrome and multiple organ failure persisted from the 5th to the 12th posttraumatic day. 
to 40-fold molar surplus of the inhibitor over the enzyme. Therefore, the obviously deficient 
inhibitory capacity of o^PI may have been caused by proteolytic and oxidative denaturation 
as well. Applying special assay systems, both ways of a, PI destruction were demonstrated 
by Schraufstatter et a l . 2 9 at least in some individual BALF samples of patients with manifest 
ARDS. Although other authors could not detect elastase activity against high molecular 
weight protein substrates in BALF samples of ARDS patients (Idell et a l . 3 0 Wewers et al . 3 1 ) , 
we were recently able to show caseinolytic activity in a variety of BALF samples (kindly 
given to us by Dr. Obertacke, Surgical Clinic, University of Essen) from trauma patients 
with severe lung dysfunctions (Machleidt et al . 1 4 ) . In vitro incubation of these specimens 
with a!PI nearly completely abolished this proteolytic activity (Figure 6) and gave rise to 
an additional increase of the elastase-c^PI complex, indicating that the enzymatic activity 
present in the alveolar environment was mostly due to PMN elastase. 
Moreover, the destructive potency of elastase in vivo could be directly documented for 
the first time by the proof of augmented generation of FEP in close correlation to the rising 
amount of the extracellularly discharged PMN enzyme in BALF samples of patients with 
aggravating respiratory failure (figure 7). Hence, the aggressive components of inflammatory 
cells, especially the lysosomal proteinases, may indeed contribute to the occurrence of lung 
dysfunctions in severely traumatized patients. 
2. Sepsis and Peritonitis 
In several prospective clinical studies on more than 200 patients suffering from bacterial 
infections afier major surgical ireaiments, we could demonstrate an increasing release of 
PMN elastase into the circulation in accordance with the worsening of the inflammatory 
reaction (Duswald et a l . 3 2 Inthorn and Jochum;33 Jochum et al . 2 3 ) . Patients without post­
operative infections showed only moderate transiently elevated plasma levels of complexed 
elastase (up to three times that of normal) after the operation, whereas onset and course of 
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FIGURE 7. Total amount of PMN elastase (measured as complex with a,-proteinase inhibitor) and fibrino-
elastase-peptide (FEP) in serial bronchoalveolar lavage fluids of a severely traumatized patient with reversible 
respiratory dysfunction from the second to the seventh posttraumatic day. 
sepsis were characterized by markedly increased concentrations up to 30-fold in individual 
cases. As a mean, in patients with persisting septicemia the elastase plasma levels remained 
significantly elevated until death, while a recovery phase was accompanied by an obvious 
return to normal values. A detailed evaluation of our data1 3 3 exhibited that in eventually 
dying patients a significant increase of complexed elastase occurred 2 to 3 d before clinical 
manifestation of severe sepsis, followed by a transient decrease and an additionally significant 
rise, when sepsis was clinically diagnosed (figure 8). In surviving patients, however, the 
tremendous increase of PMN elastase in plasma did coincide with the clinical manifestation 
of the severe infection, whereas the recovery phase was clearly indicated earlier by declining 
elastase levels compared to the clinical assessment (Figure 8). Thus, measuring PMN elastase 
in closely matched consecutive plasma samples (taken every 6 h) of severely i l l patients did 
not only allow an early diagnosis of the clinical state, but also suggested an involvement of 
the granulocytic proteinase in the development of severe infection and sepsis. 
When complexed elastase increased in plasma, a prominent reduction of the humoral 
blood cascade proenzymes, prekallikrein and prothrombin, as well as of the AT II I inhibitory 
activity, was measurable. This indicates that the proteolytic mechanisms in this pathological 
situation are quite similar to those seen in the course of developing posttraumatic organ 
failure. In addition, we could demonstrate in some pilot mesurements that during a septic 
shock phase the monocyte/macrophage-derived cathepsin Β was released in a manner similar 
to the PMN elastase, thus intensifying the extracellular proteolytic capacity.23 
Just recently we were able to verify such a destructive proteolytic potency in a still 
ongoing prospective study (clinically directed by Dr. Inthorn, Surgical Clinic Großhadern, 
University of Munich) on septic patients. To be enrolled in this investigation, patients had 
to fulfill all four previously defined septic criteria (septic focus and/or positive blood culture; 
body temperature >38.5°C; leukocytes > 15,000/1 or <5,000/1; platelets < 100,000/1 or drop 
of platelets >20% within 24 h ensuring a severe inflammatory situation. In patients with 
lethal outcome, the generation of the elastase-induced fibrinogen split product FEP was well 
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FIGURE 8. Plasma levels of PMN elastase (in complex with α,-proteinase inhibitor) in patients developing 
severe infection/sepsis. Days l to 4: clinical course with minor or without complications; days 5 to 9: clinically 
diagnosed life-threatening infection/sepsis. ( ) nonsurvivors, η — I I ; ( ) survivors, η = l l . 
correlated to high plasma levels of PMN elastase. Moreover, the unspecific proteolytic 
degradation of AT I I I , which is also susceptible to PMN elastase cleavage (Jochum et al . ; 3 4 
Jordan et al . 3 5 ) , could be pointed out by an indirect method comparing the amount of AT 
II I antigen with its inhibitory activity. In patients suffering from eventually lethal sepsis, 
AT III was not only considerably consumed (to about 50% of normal) throughout the whole 
sepsis period. The clearly lower inhibitory activity (between 20 and 40%), however, indicated 
also that part of the antigen level may be due either to inactive complexes of the inhibitor 
with clotting enzymes or to proteolytically degraded molecules. Since the latter have an only 
slightly lower molecular weight and nearly the same half-life as the intact molecules (Jordan 
et al . 3 5 ), they cannot be distinguished from the native AT I I I i f quantified by radial im­
munodiffusion. In our patients, however, we could definitely rule out the possibility that 
AT III-proteinase complexes significantly contribute to the higher antigen levels in com­
parison to the inhibitory activity; due to their very short half-life of only a few minutes, 
concentrations of AT Ill-thrombin complexes ran up at most to only 0.01% of the overall 
AT I I I amount. Thus, elastase-inactivated AT I I I molecules should be present with high 
probability in the pathological situation of severe sepsis. This assumption is further supported 
by results of Jordan et a l . 3 5 which demonstrate that even catalytic amounts of heparin react 
with elastase in a way considerably accelerating the rate of AT I I I inactivation by this 
enzyme. Since heparin exists as a minor component on vascular endothelial cells as well as 
a therapeutic drug in our patients, the positive regulation of hemostasis by heparin may be 
significantly counteracted by the adverse effect on AT I I I in case of a high release of elastase 
from PMN granulocytes adhering to the endothelial layer of the blood vessel walls. Moreover, 
as recently shown by Frommherz et a l . , 3 6 inhibition of elastase by o^PI is significantly 
retarded in the piesence of heparin, which would further allow proteolytic degradation of 
susceptible plasma proteins. 
Results confirming our findings with respect to the release of PMN elastase and the 
consumption of hemostatic proteins in more than 150 patients developing infection and sepsis 
have been extensively published by the research group of R. Egbring (review of literature 
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in Egbring et al . 3 7 and Seitz et al . 3 8 ) . The authors found not only significantly elevated 
elastase levels in septic patients, but also in subjects with cardiac shock and fulminant hepatic 
failure. Yet, the highest values (up to 50-fold that of normal) where measured in septic 
shock patients. 
In addition, Pacher et a l . 3 9 reported on a study with daily measurements of the complexed 
elastase in plasma of a heterogeneous group of patients which could be divided into 32 
septic and 24 uncomplicated postoperative and nonpostoperative cases. In these patients a 
significant difference in elastase plasma levels was seen between septic nonsurvivors and 
nonseptic patients, whereas septic survivors showed equally high levels as nonseptic post-
operative patients. Moreover, septic pulmonary insufficiency could be predicted 1 d before 
the need of mechanical ventilation by elastase levels above fourfold that of normal with a 
specificity of 80% and a sensitivity of 81%. With an even higher specificity (83%) and 
sensitivity (88%), this threshold level predicted MOF 1 d before an MOF-score of >5 was 
evaluated. These results can be taken as a further hint to the pathogenic potency of PMN 
elastase in the development of sepsis and MOF regardless of the inciting cause. 
The predictive validity of PMN elastase plasma levels for a forthcoming postoperative 
infection risk was also confirmed by Fink ei a l . 4 0 In 12 of 25 patients with colon-related 
surgical operations the complexed elastase in plasma was still significantly elevated above 
normal at the fifth postoperative day, thereby indicating a forthcoming infection at least 3 
d before the clinical verification of the complication on day 8 to 10. In uncomplicated cases, 
a steady decrease after the operation-induced elevation was noticed. In a second study of 
this research group41 on 56 intensive care patients undergoing abdominal surgery, the op-
eration procedure induced a threefold increase of elastase plasma levels in 31 patients with 
an uncomplicated postoperative course, whereas in patients with an early postoperative 
sepsis, a more than fivefold elevation above normal was measured. Ten patients who survived 
the septic episode were characterized by a steady decrease of complexed elastase and could 
not be differentiated from those without sepsis from the 48th postoperative hour onwards. 
Septic nonsurvivors (n = 15), however, showed constantly high or even additionally in-
creasing postoperative elastase levels. Thus, the authors concluded that a long lasting ele-
vation of PMN elastase is highly indicative of a serious deterioration of the septic situation. 
Just recently, Tanaka et a l . 4 2 compared daily measured elastase plasma levels of 16 
patients with septic shock complicated by MOF with those of 30 patients with hemorrhagic 
shock secondary to severe injury over a period of 1 week. Whereas in the septic patients 
the shock period lasted for more than 7 d, patients suffering from severe injury recovered 
from hemorrhagic shock within 24 h. At diagnosis of septic shock, complexed elastase was 
elevated up to a mean plasma level of eightfold above that of normal and remained high 
during the ensuing week. In hemorrhagic shock the levels were also raised up to about 
sixfold but quickly returned to normal at recovery. In this study the increase of complexed 
elastase in plasma was significantly correlated to decreases of plasmatic fibronectin and 
factor X I I I , two proteins known to be easily susceptible to proteolytic cleavage by PMN 
elastase.1,2 Significant correlation was also found between elastase activity in BALF samples 
and the respiratory index of the septic shock patients, thus suggesting that at least local 
tissue damage in sepsis and MOF may be partly due to the destructive potency of PMN 
elastase. 
Likewise, a highly significant positive correlation between the plasma levels of com-
plexed elastase and the respiratory index was reported by Shimanuki et a l . 4 3 in 49 patients 
who underwent operations of various degrees of surgical stress. As the operative intervention 
became more severe, the plasma levels of granulocytic elastase rose. Moreover, marked and 
prolonged elevation of these plasma levels paralleled postoperative pulmonary complications. 
Patients with panperitonitis showed mean complex plasma levels of more than sevenfold of 
normal before operation, whereas in noninfectious underlying diseases only slightly elevated 
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preoperative elastase levels were measured. Coinciding with our findings, 3 2 the elastase 
complex levels in cases of panperitonitis did not increase after surgery but slightly decreased 
over time, probably due to the removal of the abdominal inflammatory focus enabling a 
continuous amelioration of the infection. 
Schöffel et a l . 4 4 studied a collective of 21 patients undergoing major abdominal surgery 
in whom sepsis was diagnosed during their postoperative stay in ICU (intensive care unit). 
A persistent elevation of complexed elastase above fourfold that of normal plasma values 
beyond the third postoperative day or an additional increased (five- to tenfold) closely 
correlated with postoperative intra-abdominal infectious complications which required rein-
tervention. In those patients (n = 7) sepsis was clinically diagnosed between the third and 
sixth postoperative day. Patients with transient postoperative septic episodes showed a gradual 
normalization of elevated elastase plasma levels within the first 3 to 4 d after surgery. In 
another study monitoring the early inflammatory response in 27 peritonitis patients, the 
authors emphasized the significant predictive value of elevated elastase plasma levels at the 
time of emergency laparatomy for the later outcome (survival/death) of the patients.45 
In addition to measurements of the complexed elastase in plasma of adults, serial quan-
tifications of this granulocytic proteinase in 306 neonates carried out by Speer and Tegtmeyer46 
have proven that this inflammatory mediator is a highly sensitive and rapidly responsive 
indicator of neonatal septicemia as well as a helpful tool in monitoring the course of the 
disease. When patients with neonatal septicemia were differentiated from those with other 
neonatal disorders, elevated complexed elastase levels showed a sensitivity of 95% and 
specificity of 81 % for the septic entity. Similar results were published by Tsaka and Herkner47 
on 135 newborn infants. 
Diffuse peritonitis is often the source of a systemic spreading of local infectious com-
plications eventually leading to sepsis and MOF. In previous work, we were able to dem-
onstrate that the impairment of opsonisation in the peritoneal cavity allows the survival of 
huge numbers of bacteria despite the presence of intact phagocytes (Billing et a l . 1 1 - 4 8 , 4 9 ) . 
The proteolytic breakdown of the main opsonins immunoglobulin (IgG and complement 
factor C3 in peritonitis exudates correlated well with the extracellularly released lysosomal 
proteinases, elastase and cathepsin B, in the local body fluids. We therefore, assumed that 
these enzymes are the principal cause of the deficiency in opsonic capacity. To assure this 
supposition, isolated IgG was incubated in vitro either with PMN elastase and cathepsin Β 
or (in its isothiocyanate-labeled form = FITC IgG) with a cell-free, purulent peritonitis 
exudate (kindly supplied by Dr. Billing, Surgical Clinic Groshadern, University of Munich). 
The proteolytic degradation was followed by gel chromatography of the split products 
exhibiting the same type of IgG cleavage pattern under all conditions (Machleidt et a l . , 1 4 
Billing et al . 1 3 ) . Using resorufin-labeled casein as a substrate, similar results were obtained 
substantiating proteolytic elastase activity despite the presence of up to 40-fold molar surplus 
of a,PI antigen in peritonitis exudates. These findings closely resembled the already men­
tioned data obtained from BALF samples in trauma patients. In addition to the in vivo 
degradation of IgG and C3, we have successfully proven the generation of FEP in peritonitis 
exudates of 21 patients. As depicted in Figure 9, high amounts of complexed PMN elastase 
coincided with highly elevated FEP in the specimen drawn before surgical treatment of the 
abdomen of a patient with severe peritonitis. After rinsing the peritoneal cavity with 10 1 
of Ringer lactate solution, both parameters decreased to approximately zero. Yet, as can be 
seen from the abdominal drainage fluids collected between 0 and 1 h, 1 and 2 h as well as 
2 and 8 h after operation, the release of PMN elastase started again, inducing also the 
production of FEP (Figure 9). These observations may be taken as an indication of a still 
ongoing inflammatory reaction in this patient. 
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FIGURE 9. PMN elastase (in complex with ot,-proteinase inhibitor) and fibrino-elastase-peptide (FEP) in exudate 
samples taken before (preL.) and immediately after (postL.) lavage of the abdomen of a peritonitis patient with 
Ringer lactate solution and in drainage fluids collected between 0 to 1 h, 1 to 2 h, and 2 to 8 h after lavage. 
3. Conclusion 
Summarizing the data obtained in our clinical studies and those of other authors on 
patients suffering from multiple trauma and/or sepsis, it was clearly shown that the release 
of the phagocyte proteinases, PMN elastase and cathepsin B, beyond normal values evoked 
by the physiological turnover of the phagocytes as well as the activation of proteolytic 
clotting enzymes, closely correlated to onset and severity of the acute inflammatory reaction. 
Although not outlined in detail herein, the above-mentioned studies, investigating a causal 
relationship between the occurrence of these parameters in body fluids and the disease state, 
in most cases fulfilled all important decision tree questions formerly established by Neu-
gebauer et a l . 5 0 to verify Koch-Dale's criteria 1 and 2 for a substance being an inflammatory 
mediator or even effector. 
The inflammatory effector role proved especially true for PMN elastase, because the 
destructive potency of this proteinase could be convincingly demonstrated at least on vital 
humoral proteins in relation to the propagation of organ dysfunctions in traumatized as well 
as septic patients. Moreover, the studies corroborated, without doubt, that in patients who 
have incurred severe trauma or infection, the underlying cellular and humoral biochemical 
events are quite similar regardless of the etiology of the insult. Thus, the clinical outcome 
seems to be due to the magnitude of the inflammatory response, which of course is highest 
if trauma is superimposed by infection. 
Furthermore, an excessive local (a,PI) and systemic (AT III) consumption of proteinase 
inhibitors occurs as a main consequence of the release of lysosomal phagocyte proteinases 
and the activation of proteolytic blood cascade enzymes during severe inflammatory reac-
tions. Since this entity seems to be the most critical cause which allows the proteolysis-
induced (multiple) organ damage, supplementation of the body's inhibitor potential by 
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exogenous proteinase inhibitors — isolated from human material or produced by gene 
technology as discussed by Fritz et al . 5 1 — should be a highly promising therapeutic approach 
in traumatized and septic patients. 
B. P H A G O C Y T E PROTEINASES IN E X P E R I M E N T A L 
S E P T I C / E N D O T O X I C S H O C K 
Although novel therapeutic approaches ultimately require validation in well-controlled 
clinical trials, it is virtually always necessary to obtain preliminary data in animals before 
applying new drugs or devices in humans. Thus, progress in sepsis research continues to 
depend upon studies using clinically relevant animal models and fulfilling commonly ac­
cepted criteria of the sepsis syndrome. Being applicable to both human and laboratory studies, 
the working definition of the sepsis syndrome comprises a constellation of clinical and 
laboratory findings indicative of a generalized inflammatory response leading to acute organ 
dysfunctions often, but not invariably, associated with the presence of serious bacterial, 
fungal, or viral infection. Furthermore, the septic shock phase is characterized by the cir­
culatory decompensation (i.e., hypotension) due to an exacerbation of the septic syndrome. 
To achieve such a clinic-like situation in an experimental setting, a variety of different 
approaches have been performed (extensively reviewed by Fink and Heard52). Out of those, 
intravenous infusions of viable bacteria or of endotoxins (the main toxic cell wall constituents 
of Gram-negative bacteria) belong to the most common procedures. Although there are 
considerable doubts about the absolute clinical relevance of these approaches (e.g., because 
of differences in the hemodynamic responses depending on the amount of the deleterious 
agent and the application period) it turned out that experimental bacteremia or endotoxinemia 
may provide a reasonable paradigm for sepsis in humans given the proviso that the animal 
model chosen adequately replicated those features of the clinical syndrome which should be 
explored in the experiment (e.g., release of phagocyte proteinases in relation to organ 
dysfunctions). 
With respect to the relevant animal species selected in the different laboratory models 
of sepsis and septic shock, dogs, pigs, and nonhuman primates proved to be invaluable in 
the exploration of the underlying pathobiochemical mechanisms, because of the obvious 
similarities of these animals to humans concerning physiology and biochemical reactions. 
1. Release of PMN Elastase and Cathepsin Β 
The release of granulocyte elastase and its interaction with plasma proteins was shown 
for the first time by Aasen and Ohlsson53 in a controlled prospective study on dogs (n = 
6) receiving a slow infusion of a lethal dose of E. coli endotoxin. During the endotoxin 
infusion, a marked decline in blood pressure and leukocyte counts was paralleled by a rapid 
increase of granulocyte elastase in complex with a,PI in circulating blood. Maximal values 
(determined by radial immunodiffusion) were reached at the end of the endotoxin infusion 
followed by continuously high levels up to the lethal outcome. Control animals (n = 4) 
infused only with sterile isotonic saline did not reveal such an increased release of PMN 
elastase. Antigen concentrations of the complement factor C3 in endotoxic dogs were grad­
ually reduced to about 40% of the initial values at the end of the observation period. Moreover, 
crossed Immunoelectrophoresis with antiserum against C3 indicated proteolysis of this com­
plement factor and formation of related cleavage products. As reported elsewhere, the authors 
have also noted consumption of coagulation factors, reduced levels of components of the 
plasma kaliikrein-kinin system and activation of the fibrinolytic system during the endotoxin 
experiments (review of literature in Reference 53). In control animals, only insignificant 
changes of these plasma proteins occurred. In a recent paper,54 this research group published 
a pronounced structural identity of dog and human granulocyte elastase and the development 
of a specific ELISA test system for the determination of the canine elastase-α,ΡΙ complex 
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similar to that which we and others have used for human elastase. Confirming earlier results, 
slow intravenous infusion of a lethal dose of E. coli endotoxin in seven dogs over a period 
of 2 h evoked a drop in blood pressure simultaneously with a tremendous increase (20- to 
30-fold that of normal) of complexed elastase in plasma between the 3rd and 12th h after 
starting the experiments. Plasma levels were much higher in the dogs that died during the 
observation period as compared to the survivors. Interestingly, concentrations of complexed 
elastase in plasma of normal control and endotoxic dogs, respectively, were strikingly similar 
to those of healthy humans or septic patients. 
In contrast to dog and human granulocytes, porcine PMN leukocytes contain proteolytic 
as well as inhibitory activities. As shown by Geiger and colleagues (review of literature in 
Geiger et al . 5 5 ) , the main inhibitory activity against lysosomal neutral serine proteinases 
such as elastase resides as a cytosolic serpin-like inhibitor, called leukocyte neutral proteinase 
inhibitor (LNPI). This inhibitor is released simultaneously with elastase due to stimulation 
or disintegration of the PMN cells and inhibits effectively this enzyme outside of the gran­
ulocytes. Thus, applying a specifically developed ELISA test system, quantification of the 
elastase-LNPI complex in porcine plasma turned out to be a reliable measure of the extra-
cellularly discharged PMN constituents.55 Mean plasma levels of this complex in healthy 
pigs reached 16 ± 11 ng/ml. In a preliminary study on eight septic pigs, levels up to 25 
times higher were observed during the development of septicemia induced by 2-h infusion 
of live E. coli.55 Maximal values were measured about 10 h after the end of the bacterial 
application. These results could be clearly confirmed in a second randomized trial, in which 
the release of the porcine PMN constituents was highly correlated with the occurrence of 
hypotension and hypoproteinemia due to infusion of viable bacteria.56 In another prospec­
tively controlled randomized, short-term study performed by our research group57 a similar 
significant increase of PMN elastase in complex with LNPI above normal was noticed 
concomitantly to the development of organ dysfunctions in 18 pigs receiving a continuous 
infusion of Salmonella abortus ec/ui endotoxin over the whole observation period of 6 h. 
No such changes occurred in sham-treated control animals. 
In addition to the proof of PMN elastase release in septic/endotoxic situations, pigs are 
the only animal species in which an extracellular discharge of the monocyte/macrophage-
derived cysteine proteinase cathepsin Β above normal has been reliably demonstrated after 
endotoxin infusion so far.9-5 8 Starting from a normal level of about 200 mU/1 (corresponding 
to fourfold that of normal values in healthy humans) intravenous infusion of 5. abortus equi 
endotoxin for 6 h in 19 pigs evoked a steady increase of cathepsin Β in plasma up to 3.5-
fold that of normal at the end of the 6-h observation period.9 Concomitant to this increase, 
a significant decrease in arterial blood pressure occurred, indicating a severe septic shock 
state. In contrast, sham-treated control animals (n = 7) did not show any remarkable, 
pathophysiological changes. Similar results could be demonstrated in another randomized 
trial with 11 pigs receiving also a 6 hour-continuous infusion of S. abortus equi endotoxin.5 8 
In this study, the endotoxin-induced rise of cathepsin Β was partially reduced in 13 animals 
treated with the platelet activating factor (PAF) receptor antagonist WEB 2086 compared 
with the 11 septic untreated controls indicating that the cathepsin Β release may have been 
mediated to some extent by PAF in this experimental setting. 
Due to obvious similarities between humans and baboons especially with regard to the 
antigenic identity of many plasma and cellular proteins, a modified version of the ELISA 
test system for human PMN elastase can easily be applied for quantification of this gran­
ulocyte proteinase in plasma of baboons. As recently shown by Redl et a l . , 5 9 using this test 
system, continuous intravenous administration of live E. coli over 8 h in seven baboons 
evoked a massive release of PMN elastase from within 1 h after starting the experiment to 
the end of the observation period. Although normal plasma levels of extracellularly dis­
charged PMN elastase in baboons reached only one third that of humans, the 20- to 30-fold 
increase in septic animals was highly comparable to the situation in septic patients. 
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As already reported by Egbring and Havemann (1978), 6 0 a bolus infusion of 50 g S. 
abortus equi endotoxin per kilogram of body weight in a green monkey induced not only 
the release of PMN elastase within 20 to 300 min after the endotoxin injection — as 
demonstrated by one-dimensional Immunoelectrophoresis — but also a concomitant decrease 
in activity of several coagulation factors quite similar to findings in septic patients.37-38-60 
2. Eliciting Inflammatory Reactions by Exogenous Administration of Elastase 
Because of ethical objections it is nearly impossible, under clinical conditions to verify 
the Koch-Dale criterion 3, which is eliciting pathophysiological reactions comparable to 
those seen during septic inflammation by the exogenous administration of a putative in-
flammatory mediator. Even in animal experiments such studies can be performed only with 
great limitations (e.g., insufficient amount of the isolated substance available). Thus, until 
now, just a few data were published concerning the assumed pathogenetic role of lysosomal 
proteinases exogenously applied to experimental animals. 
In a very preliminary, early approach Egbring and Havemann60 infused highly purified, 
endotoxin-free human PMN elastase (7 mg/kg body weight) in green monkeys. Immediately 
after the intravenous injection, elevated complexed elastase in plasma could be detected 
using a specific antihuman elastase antibody. Thereafter, the level steadily decreased until 
only minute amounts of the granulocyte enzyme could be seen at 6 h postinjection. After 
24 h, the animals' circulation had been virtually cleared of the complexed human PMN 
elastase. Simultaneously, to the maximal increase of elastase, a pronounced inactivation of 
the clotting factors I I , V, V I I I , and (to a less degree) X I I occurred. Reduction of fibrinogen 
and generation of its split products were somewhat delayed (maximum between 30 to 60 
min), whereas factor XI I I activity decreased over a period of 24 h. During the test period 
no changes in peripheral blood cell counts were observed, yet a moderate bleeding tendency 
appeared as was indicated by skin hematoma and bleeding gums. Although no further signs 
of a sepsis-like syndrome became obvious, presumably due to a too low and short-lasting 
exogenous elastase administration in these animals, the given changes can be taken as a first 
hint to the involvement of PMN elastase in sepsis-associated clotting disorders. 
In contrast to the relatively limited data on proteinase-induced tissue damage of the lung 
in septic inflammation, intensive studies on pulmonary emphysema were performed several 
years ago by Janoff and colleagues61-62 as well as by many other researchers.63 The results 
indicate that the "proteinase pathogenesis" of this chronic disease may be fairly comparable 
to that of the ARDS in septic MOF. Interestingly, in one of the studies,61 instillation of a 
certain amount of purified human PMN elastase is isolated-perfused dog lungs produced an 
anatomic emphysema nearly identical to that evoked by porcine pancreatic elastase. No-
nelastolytic proteinases, including trypsin, chymotrypsin, and collagenase, failed to induce 
emphysematous changes in this test system. Moreover, localized endotracheal instillation 
of human PMN elastase or porcine pancreatic elastase, respectively, in living dogs revealed 
similar dose-dependent, proteolysis-elicited lesions of the lung tissue even in the presence 
of normal concentrations of circulating and local proteinase inhibitors. These data demon-
strate a high functional identity of human PMN elastase with porcine pancreatic elastase 
despite an obvious divergent origin of the proteinases. 
Taking advantage of this identical pathogenic potency of the two elastolytic lysosomal 
proteinases, Stokke and colleagues studied the effect of a 3 to 5 h continuous intravenous 
infusion of porcine pancreatic elastase (ca. 6.6 mg/kg bw/h) into normal (n = 9) or agran-
ulocytic (n = 4) minipigs concerning the development of ARDS and blood coagulation 
disorders.64 6 6 Since in normal and agranulocytic minipigs the continuous intravenous infusion 
of elastase led to an early equal impairment of pulmonary hemodynamics and gas exchange 
functions, the authors assumed that these effects may be mediated by the elastase-induced 
activation of other cascade systems (e.g., complement factors and arachidonic acid metab-
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olites) rather than by elastase itself. Moreover, increase in capillary permeability, evoking 
an ARDS-like interstitial edema, was prevented in agranulocytic pigs, whereas in normal 
animals elastase infusion induced a massive pulmonary granulocytosis combined with the 
development of interstitial edema and progressive respiratory failure. Thus, the release of 
further proteinases and other inflammatory mediators such as toxic oxygen compounds from 
sequestered granulocytes either directly or indirectly stimulated by the exogenous elastase 
— may have led to the destruction of the lung tissue. 
In addition, pancreatic elastase infusion in normal minipigs caused a pronounced hy-
pocoagulability with degradation of the clotting factors V, V I I , V I I I , Χ, X I I I , fibrinogen, 
and AT 111, whereas in granulocyte-depleted animals mainly factor XII I and AT I I I were 
consumed at the end of the short-term experiments. These results can be taken as a further 
hint to the proteolytic potency of activated granulocytes under pathological conditions. 
Since all measured parameters remained unchanged in a control group (n = 3), the 
given data clearly indicate that elastase (mainly of PMN origin) may be involved in the 
pathophysiology of acute lung failure and defects in the blood coagulation seen during the 
septic-like syndrome in animals and humans. But obviously, the PMN elastase is only one 
inflammatory factor in a very complex mechanism of interactive mediator-releasing cascade 
systems. 
3. Conclusion 
As demonstrated in the preceding sections, the demands for being a causal chemical 
factor in the sepsis syndrome according to the Koch-Dale criteria 1 and 2, which mean 
presence of an inflammatory mediator in disease and its absence (beyond normal physio­
logical concentrations) in health,50 could be confirmed for PMN elastase and monocyte/ 
macrophage-derived cathepsin Β not only in humans but also in several animal models on 
experimental septic/endotoxin shock. Moreover, administration of animal exogenous elas-
tases (of PMN cell or pancreatic origin) elicited pathophysiological reactions similar to those 
observed during septic inflammation. Thus, not disregarding the limitations of the underlying 
experiments, at least PMN elastase fulfilled the Koch-Dale criterion 3 for being a putative, 
although not the sole, causal inflammatory mediator in such a disease state. 
C . PROTEINASE INHIBITION AS A S U I T A B L E T H E R A P E U T I C APPROACH 
IN A C U T E INFLAMMATION 
To further establish the ultimate relevance of a putative causal mediator in acute in­
flammation such as septic shock, the use of specific mediator antagonists as therapeutic 
tools should prevent or at least reduce to some extent severe signs of inflammation in 
accordance with Koch-Dale criterion 4 as indicated by Neugebauer and Lorenz.6 7 Since 
especially PMN elastase turned out to play a major role in shock-associated organ and 
hemostasis dysfunctions, accomplishing the demands of the first three Koch-Dale criteria, 
we and others envisaged the therapeutic application of elastase inhibitors as the most prom­
ising approach to interfere with proteolysis-induced pathomechanisms in acute inflamma­
t i o n . 8 5 1 6 8 Moreover, the excessive consumption of AT III during severe inflammatory 
reactions, which enables an unrestricted activity of hemostatic proteinases further intensifying 
the overall pathological proteolysis, should be compensated by the exogenous administration 
of potent thrombin inhibitors. 6 9- 7 0 
Yet, before applying such drugs in humans, especially those of nonhuman origin gen­
erated by gene technology or chemical synthesis,51 safety and efficacy first has to be 
demonstrated in convenient animal models. 
1. Inhibitors of PMN Elastase or Thrombin in Experimental Septic/Endotoxic Shock 
In a preliminary, controlled study on sepsis in young pigs, the prophylactic application 
of the relatively specific recombinant elastase inhibitor, eglin c (originally isolated from the 
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leech Hirudo medicinalis), caused a significant reduction in the consumption of AT I I I and 
other plasma proteins as well as in the formation of interstitial pulmonary edema (Jochum 
et al . 7 1 ) . As assessed by measurement of arterial blood pressure and total protein concentration 
in plasma, in a more extended study, Siebeck et a l . 5 6 , 7 2 demonstrated that eglin c can also 
reduce hypotension and the overall capillary leakage induced by the infusion of live E. coli 
in pigs. In this study, significantly lower concentrations of the elastase-LNPI complex in 
plasma were measured under eglin c administration, presumably indicated an extremely rapid 
competition of the exogenous elastase inhibitor with the granulocyte-derived serine proteinase 
antagonist LNPI . 5 6 Such a rapid complexation by eglin c seems to prevent proteolytic activity 
of released elastase more effectively than by the endogenous inhibitor. 
Moreover, in another controlled investigation, Siebeck, Hoffmann, and colleagues,57-73 
showed that besides eglin c, the thrombin-specific inhibitor hirudin — another recombinant 
inhibitor also formerly isolated from the medical leech — significantly improved endotoxin 
shock syndromes in minipigs. Fibrinogen consumption, formation of fibrin monomers as 
well as the occurrence of pulmonary vasoconstriction and the release of PMN constituents 
(elastase, LNPI) were clearly lower in endotoxemic animals treated prophylacticly with 
hirudin as compared to those without continuous intravenous inhibitor infusion. Since hirudin 
does not interfere with PMN elastase inhibition by endogenous inhibitors, the conclusion 
can be drawn that the activation of clotting enzymes, which are known as potent, direct or 
indirect stimulators of the PMN cells, 7 4 7 6 was effectively reduced by inhibition of thrombin, 
thus also lowering the stimulation of PMN granulocytes. 
Interestingly in another randomized porcine endotoxin shock model, the supplementation 
of a purified AT III-heparin complex had only a slight, nonsignificant positive effect on the 
endotoxin-induced mortality and the oxygen saturation in arterial blood (as an indication of 
pulmonary function), even though the consumption of fibrinogen and the formation of soluble 
fibrin monomers were clearly prevented in the drug-treated animals (Spannagl et al . 7 7 ) . 
Furthermore, prothrombin consumption was similar in the treatment and placebo groups 
suggesting that local thrombin generation, via factor Xa and binding of both enzymes to 
endothelial cell membrane receptors, may protect them from inhibition by the AT III-heparin 
complex. On the other hand, the applied amount of the AT III-heparin complex may not 
have been sufficient to inhibit the activation of contact phase enzymes (plasma kallikrein, 
factor Xlla) which are supposed to be potent stimulators of PMN granulocytes74-75 as pre-
viously mentioned. Therefore, the inflammatory process might have been maintained pri-
marily via the release of phagocyte proteinases and reactive oxygen metabolites. Moreover, 
since after an initial rise (up to about 130%), the AT I I I activity decreased during further 
drug application while the antigen level still increased, the heparin in the complex may have 
also facilitated the inactivation of AT I I I by released PMN elastase (Jordan et al. 3 5) thereby 
lowering the inhibitory capacity under an otherwise presumably effective threshold level. 
The requirement of high levels of AT I I I inhibitory activity in the circulation is also 
confirmed by results of Emerson et a l . 7 8 concerning the efficacy of AT I I I supplementation 
in several animal models (rat, sheep, and baboon) of fulminant E. coli endotoxemia or 
bacteremia. Only very high dosage (up to threefold of normal) and prophylactic adminis-
tration of AT I I I prevented organ damage and increased permanent survival in the experi-
mental animals. Interestingly, the combined application of AT I I I and a!PI showed a sig-
nificant, synergistic improvement of the pulmonary function compared to the single drug 
treatment in the endotoxemic sheep model. This indicates again that a complex interaction 
of lysosomal and humoral blood cascade proteinases contributes to the perpetuation of a 
septic-like inflammation. 
2. Antithrombin I I I Supplementation in Clinical Sepsis 
Beside the therapeutic animal experiments, preliminary clinical studies (reviewed in 
References 69, 70, and 80) have also proven the postulated positive effects of thrombin 
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inhibition on the hemostatic system by AT I I I supplementation in severely il l patients. Yet, 
a statistically significant reduction in MOF or lethality compared to untreated patients could 
be verified in only a few trials. Since in these studies just normal plasma levels of AT I I I 
were achieved by the applied therapeutic regimen infusing purified human AT I I I concen-
trates, we draw the conclusion that only AT I I I levels well above the normal plasma range 
may be able to interfere with phagocyte-derived inflammatory reactions, thus improving not 
only disseminated intravascular coagulation but also organ dysfunctions in clinical sepsis. 
In addition, this assumption is especially supported by our animal experiments77 and those 
of Emerson et a l . 7 8 
Therefore, we conducted a prospective, randomized study (clinically directed by Dr. 
Inthorn, Surgical Clinic Großhadern) on septic patients with the aim to increase the AT II I 
inhibitory activity at least above 120% of normal. To achieve this, AT III concentrates were 
intravenously infused twice daily over 21 d according to a modified regimen originally 
described by Blauhut et al . 8 1 Blood samples were taken twice daily throughout the entire 
observation period. Preliminary data and a detailed outline of the performance of the still 
ongoing trial have been published by Jochum et a l . 8 2 Here, only the most important results 
will be presented. Up to now, 15 patients — fulfilling previously mentioned septic criteria 
— could be enrolled in each of the groups (control and therapy). 
With our application scheme, the AT I I I activity in the treatment group was elevated 
to mean plasma levels slightly below 120% during the first 9 d, followed by an increase 
above 120% thereafter, whereas in the control group levels between 60 (early phase) and 
80% (later phase) were measurable. Although all AT Ill-treated patients received nearly the 
same amount of the inhibitor concentrate (between 8000 and 4000 U/d), those individuals 
who survived the septic event showed clearly higher AT II I levels (up to a mean of 135% 
during the first 5 d after sepsis diagnosis) than patients who died despite of AT I I I supple-
mentation (mean AT I I I activity between 100 and 115% in the early septic phase). Thus, 
immediate AT I I I substitution in sufficiently high amounts after early diagnosis of a septic 
episode appears to be of great importance in improving the survival of the patients. 
Probably due to a too-late onset of the inhibition therapy in addition to the application 
of still insufficiently high AT I I I dosages in some of our patients, the overall mortality could 
be only reduced from 87% in the control group to 60% in the AT Ill-treated collective. This 
diminution in lethality was statistically nonsignificant, yet a clear improvement of organ 
functions — especially of lung, liver, and kidney — in the treated patients as well as a 
further deterioration in the control group became evident. 
Mean plasma levels of complexed elastase were elevated up to sixfold of normal upon 
admission and decreased gradually to about threefold in both groups until the end of the 
observation period. Although there were no statistically significant differences, a slight trend 
to lower plasma elastase levels appeared in the AT I I I group. Similar minute distinctions 
were seen in AT Ill-treated patients who survived compared to those who died. An obvious 
reduction of complexed elastase in plasma due to AT I I I supplementation was demonstrated 
by Seitz et a l . 7 7 
In our study, plasma prekallikrein and prothrombin levels were reduced up to 30 and 
50%, respectively, upon sepsis diagnosis and showed a more or less pronounced change to 
higher values (40 and 80% of normal) later without distinct differences in the placebo and 
treatment groups. Interestingly, however, prekallikrein levels rose steadily to 50% in AT 
Ill-treated survivors, whereas in the nonsurvivors a further transient decrease to 20% oc-
curred. An analogous behavior was observed for prothrombin which reached 80% of normal 
10 d after onset of sepsis in the AT Ill-treated survivors, while in the moribund patients 
plasma prothrombin levels as low as 60% were measured at that time. Thus, the rise in AT 
II I inhibitory activity to nearly 140% in the early septic phase may have been beneficial 
enough to preserve clotting proenzymes from excessive activation throughout a septic period. 
Nevertheless, it became obvious from our findings that a convincing improvement of the 
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overall septic state deserves an even higher and earlier substitution of AT I I I than that applied 
in this study. 
3. Conclusion 
The given data derived from the therapeutic experimental and clinical studies on acute 
inflammation unequivocally indicate that proteolytic pathomechanisms due to phagocyte and 
hemostasis proteinases play an important role in the onset and perpetuation of inflammatory 
processes such as sepsis-induced multiple organ dysfunctions. Therefore, plasma levels of 
regulatory elastase and thrombin inhibitors have to be elevated by a suitable supplementation 
and kept well above the normal inhibitory activity in healthy people to achieve a significant 
improvement of the clinical situation in severely i l l patients. 
Yet, despite the fact that the leech-derived elastase and thrombin inhibitors, eglin c and 
hirudin, have shown a high efficacy in animal experiments, their clinical application has to 
be considered with caution, especially concerning a putative antigenicity of nonhuman 
proteins in long-term studies. Thus, a therapeutic approach with isolated, purified human 
plasma inhibitor preparations (c^PI, AT III) is the only clinical choice at present. 
Although the natural sources for the isolation of proteinase inhibitors from human 
material are very limited, the design of highly effective inhibitory proteins on the basis of 
human inhibitor molecules by molecular modeling and their production by recombinant DNA 
technology is the most promising approach to get the quantities necessary for proteinase 
inhibition therapy in the future (Fritz et al . 5 1 ) . 
IV. SUMMARY 
As outlined in detail by Neugebauer et a l . , 5 0 several years ago, more than 100 different 
mediators were described as being causally related with acute inflammation and circulatory 
shock. Despite, or probably because of, the fact that for none of these factors unequivocal 
proof of its ultimate relevance had been given until now, there is still a growing number of 
new mediators which are supposed to play the central role in an acute inflammatory process 
such as multiple trauma and sepsis. Yet, to establish a cause-effect relationship of a single 
mediator in shock the classical criteria of Koch-Dale (being a causal chemical factor in a 
pathological reaction) should be considered in a modified version using the method of meta-
analysis and models of decision trees as suggested by Neugebauer et a l . 5 0 and Neugebauer 
and Lorenz. 6 7 
Being aware of the fact that not a single factor, but a mixture of causal inflammatory 
mediators is acting in concert to evoke a sepsis-like syndrome following severe trauma, 
major surgery, or infection, we have been especially interested in the extent proteolytic 
pathomechanisms may participate in the initiation and perpetuation of these acute inflam-
matory processes. Although we did not use meta-analysis procedure and models of decision 
trees in detail, a more or less narrative review of our research work and that of other authors 
with respect to the topic of interest revealed a prominent role of proteinases in acute in-
flammation. This statement is based on the following indications: 
1. The release of the lysosomal phagocyte proteinases, PMN elastase, and monocyte/ 
macrophage-derived cathepsin B, as well as the activation of proteolytic blood cascade 
enzymes in correlation to the severity of trauma-, surgery-, and/or bacteria-induced 
inflammation could be clearly verified in a variety of clinical and experimental animal 
studies. Moreover, in humans, the amounts of the extracellularly discharged phagocyte 
proteinases in plasma at an early stage of the disease were highly predictive for 
forthcoming organ failure and ultimate outcome. 
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2. The consumption of proteinase inhibitors (α,PI, AT III) and other plasma proteins 
susceptible to proteolytic degradation coincided with the occurrence of proteolytic 
activity, especially that of PMN elastase. 
3. Split products of functional proteins specifically generated by the phagocyte proteinases 
could be demonstrated in local and systemic human body fluids in correlation to the 
extracellular release of these enzymes. 
4. Exogenous administration of PMN elastase and porcine pancreatic elastase in animals 
evoked pathophysiological reactions similar to those observed during septic inflam­
mation. 
5. The therapeutic use of specific PMN elastase or thrombin inhibitors in experimental 
septic/endotoxin shock or clinical sepsis, respectively, prevented or at least reduced 
to some extent severe signs of inflammation. 
Yet, despite these convincing data the ultimate assessment of the relevance of proteolytic 
enzymes in shock states notwithstanding the numerous other candidates, requires the ap­
pliance of the probabilistic model suggested by Neugebauer and Lorenz6 7 exhibiting the 
factor of interest as a necessary, sufficient, or contributory determinant. 
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